| Literature DB >> 35433974 |
Minghui Tian1, Hua Gao2, Hongfei Jiao3, Hongbin Tian4, Lulu Han5, Xiaowan Lin1, Gong Cheng1, Fenglei Sun6, Bo Feng7,8.
Abstract
Background: This study sought to examine the mechanism of the Jian Pi Tiao Gan Yin in the treatment of obesity by network pharmacology.Entities:
Keywords: Jian Pi Tiao Gan Yin; molecular docking; network pharmacology; obesity
Year: 2022 PMID: 35433974 PMCID: PMC9011268 DOI: 10.21037/atm-22-553
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
TCM active ingredients and disease targets
| No. | TCM | Active ingredient | Disease targets |
|---|---|---|---|
| 1 | Raw Astragalus | 16 | 426 |
| 2 | Bupleurum chinense | 13 | 319 |
| 3 | Poria cocos | 6 | 27 |
| 4 | Radix Paeoniae Alba | 8 | 115 |
| 5 | Yimi | 6 | 45 |
| 6 | Salvia miltiorrhiza | 59 | 855 |
| 7 | Perrin | 7 | 111 |
| 8 | Cassia seed | 12 | 107 |
| 9 | Alisma orientalis | 7 | 9 |
| 10 | Rhubarb | 7 | 99 |
| 11 | Hawthorn | 6 | 274 |
TCM, traditional Chinese medicine.
Figure 1Network of traditional Chinese medicine compound targets of the Jian Pi Tiao Gan Yin.
Figure 2Intersection diagram of the active ingredients of the drugs and disease targets.
Figure 3The protein-protein interaction network of the Jian Pi Tiao Gan Yin in obesity.
Figure 4The protein-protein interaction network of the common targets of the Jian Pi Tiao Gan Yin and obesity.
Figure 5Enrichment analyses of the potential targets of the Jian Pi Tiao Gan Yin in the treatment of obesity. BP, biological process; CC, cellular component; MF, molecular function; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
Figure 6Network of target-pathways.
Molecular docking results of the active drug ingredients and core targets
| Compound | Binding energy (kcal/mol) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AKT1 | IL-6 | VEGFA | TNF | TP53 | CASP3 | PTGS2 | MAPK1 | JUN | EGF | |
| Quercetin | –7.34 | –5.60 | –5.88 | –7.82 | –5.87 | –6.21 | –6.14 | –5.27 | –7.16 | 5.48 |
| Kaempferol | –7.63 | –5.61 | –5.88 | –7.23 | –6.14 | –5.99 | –7.00 | –4.45 | –6.89 | 5.71 |
| Stigmasterol | –8.76 | –6.61 | –8.02 | –9.37 | –8.39 | –8.59 | –10.35 | –8.43 | –7.92 | –8.62 |
| Luteolin | –7.70 | –5.70 | –6.11 | –7.70 | –7.06 | –6.20 | –7.74 | –5.83 | –7.62 | –5.67 |
| Isorhamnetin | –7.66 | –4.90 | –6.25 | –6.87 | –6.13 | –6.33 | –6.68 | –5.05 | –5.06 | –5.54 |
| Beta-sitosterol | –8.88 | –6.23 | –7.63 | –9.60 | –8.48 | –8.76 | –10.63 | –8.46 | –8.29 | –7.91 |
| Aloe-emodin | –6.02 | –3.76 | –4.70 | –6.78 | –4.79 | –4.71 | –5.89 | –4.51 | –5.34 | –5.00 |
| Hederagenin | –8.82 | –6.78 | –7.37 | –10.80 | –8.79 | –9.32 | –8.95 | –8.10 | –7.97 | –7.87 |
| Tanshinone IIA | –7.42 | –7.21 | –7.38 | –7.39 | –6.72 | –6.53 | –8.61 | –6.64 | –7.70 | –7.11 |
| Formononetin | –7.27 | –7.21 | –7.39 | –7.57 | –8.30 | –6.63 | 8.46 | –6.64 | –7.55 | –7.11 |
IL-6, interleukin-6; VEGFA, vascular endothelial growth factor A; TNF, tumor necrosis factor; CASP3, caspase-3; PTGS2, prostaglandin-endoperoxide synthase 2; MAPK1, mitogen-activated protein kinase 1; EGF, epidermal growth factor; TP53, tumor protein 53.
Figure 7Molecular docking model diagram of the key pharmacodynamic substances-core targets. IL-1, interleukin-1; VEGFA, vascular endothelial growth factor A.